All PlansCoverageMedium impact
Avoid the Inappropriate Use of Antipsychotic Medication in Anxiety Disorders
BCBS New Mexico·NM · Psychiatry, Family Medicine, Internal Medicine·General
Effective date
Jan 14, 2026
We identified it
Jun 18, 2026
Summary
BCBS New Mexico issued guidance discouraging the inappropriate use of antipsychotic medications for anxiety disorders, as most antipsychotics are not FDA-approved for anxiety conditions like panic disorder and generalized anxiety disorder. The policy emphasizes following evidence-based clinical practice guidelines and includes quality measures for metabolic monitoring when antipsychotics are prescribed.
Action Required
By January 14, 2026: Behavioral health providers and prescribing physicians should review current antipsychotic prescriptions for anxiety disorder patients to ensure clinical appropriateness. Update documentation templates to include risk-benefit assessments when prescribing antipsychotics off-label for anxiety. Ensure metabolic monitoring (diabetes and cholesterol screening) is scheduled for patients on antipsychotics to meet NCQA quality measures.